Telegram VKontakte Yandex Youtube

Latest news

News

Novo Nordisk taps OpenAI to regain obesity drug market share

Danish pharmaceutical giant Novo Nordisk is integrating artificial intelligence from US-based OpenAI across all its divisions to accelerate drug development, the company said. The...
News

Russia deploys first personalised cancer vaccine against colorectal cancer

The first patient with colorectal cancer has begun receiving a personalized peptide therapeutic vaccine called Oncopept, Russia's Federal Medical-Biological Agency (FMBA) told GxP News....
News

Russia’s Sechenov University to launch reference centre for treating metastatic liver cancer

A reference centre for treating advanced cancers that have spread to the liver is being established at the hospital surgery clinic of First Moscow...
News

CAR-T therapy used for first time to suppress three autoimmune diseases

German researchers have developed an approach that uses CAR-T therapy — a treatment originally designed for cancer — to precisely destroy pathogenic immune cells...
News

Russia’s Federal budget provides 1.5 bln rouble boost for genetic research centres

Federal budget funding for five Russian genomic centres totalled 1.5 billion roubles in 2025, with each centre receiving 300 million roubles, Deputy Prime Minister...
News

Russian scientists develop new approach to computer modelling of drugs

Scientists at the Russian Academy of Sciences' Institute of Cytology have developed a model that improves the accuracy of predicting how potential drug compounds...
News

Russian pharma market reaches 2.9 trillion roubles, up 17% in 2025 – report

The Russian pharmaceutical market continues to show strong positive growth. Its volume reached 2.9 trillion roubles by the end of 2025, an increase of...
News

Russian drugmaker R-Pharm to study goflicicept and olokizumab in Still’s disease patients

Russia’s Ministry of Health has approved an international, multicentre, double-blind, randomised, placebo-controlled clinical trial of goflicicept and the second-line therapy drug olokizumab in patients...

Most popular

«GxP News» — зарегистрированный товарный знак. Использование названия на латинице осуществляется на основании свидетельства Роспатента № 920870 от 03.02.2023 г. в соответствии с п. 3 ст. 3 Федерального закона от 01.06.2005 № 53-ФЗ «О государственном языке Российской Федерации». Все права защищены. © 2019–2026 ООО «Медиа-Фарм Новости».

Воспроизведение материалов допускается только при соблюдении ограничений, установленных правообладателем, при указании автора используемых материалов и ссылки на портал GxP News как на источник заимствования.

18+

WordPress Ads